Treatment with Subcutaneous Infliximab for Crohn's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy of subcutaneous infliximab, with and without immunomodulators, for treating moderate to severe Crohn's disease. It is a multicenter, randomized controlled trial designed to assess the proportion of patients achieving corticosteroid-free clinical remission and endoscopic response after 26 weeks of treatment. The study aims to enroll 158 participants across approximately 20 sites in the Netherlands, focusing on patients who have not responded to or have experienced side effects from previous treatments. Participants will be monitored for their response to the treatment and any adverse effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients 18 years or older diagnosed with Crohn's disease
2. Patients with moderate to severely active Crohn's disease with a Crohn's Disease Activity Index (CDAI) of 250 to 450 and presence of endoscopic ulceration in the terminal ileum, colon or both. Minimal SES-CD is ≥ 6 or ≥ 4 for isolated ileal disease.
3. Patients who had no response or loss of response to or have had intolerable side effects to one or more to the following: glucocorticoids, thiopurines (azathioprine/6-mercaptopurine/6-thioguanin), methotrexate , adalimumab, vedolizumab or ustekinumab OR patients in need of immediate top-down treatment with IFX at the discretion of the treating physician.
4. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements.
5. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedure.
6. Male or non-pregnant, non-lactating females. No wish to become pregnant in the coming 26 weeks.

Exclusion Criteria:

1. Patients at imminent need of surgery as judged by the treating clinician
2. Patients with the short bowel syndrome, an ostomy or a symptomatic non-inflammatory stricture
3. Patients previously exposed to IFX (intravenous or subcutaneous)
4. Previously unacceptable side effects or intolerance to all immunosuppressants (both thiopurines and methotrexate)
5. Treatment with adalimumab or vedolizumab or ustekinumab within 30 days
6. Patients who have had a primary non-response to adalimumab or had intolerable class-related side effects (as evaluated at the discretion of the treating physician)
7. Enteric pathogens (such as Salmonella, Shigella, Yersinia, Campylobacter and C. difficile) detected by stool analysis within 2 weeks prior to enrollment or at screening
8. Ongoing participation in another interventional trial
9. Patients with Ulcerative Colitis or Inflammatory bowel disease unclassified (IBD-U)
10. Patients with ongoing abdominal or undrained perianal abscess
11. Patients with a history of colon cancer or colonic dysplasia, unless sporadic adenoma, which has been removed
12. Active or latent tuberculosis (screening according to national guidelines). Except when the latter has been treated appropriately according to national guidelines.
13. Cardiac failure in the New York heart Association (NYHA) stage III-IV
14. History of demyelinating disease
15. Recent live vaccination (≤ 4 weeks)
16. Patients with ongoing acute/chronic infection (including but not limited to HIV, hepatitis B and C) with the exception of chronic herpes labialis or cervical human papillomavirus (HPV)
17. History of cancer in the last 5 years with the exception of non-melanoma skin cancer
18. Male patients with Epstein-Barr virus (EBV) negative serology
19. A history of alcohol or illicit drug use that in the opinion of the principal investigator (PI) would interfere with study procedures
20. Patients with psychiatric problems that in the opinion of the PI would interfere with study procedures
21. Patients unable to attend all study visits
22. Patients with a history of non-compliance with clinical study protocols
23. Contraindication for endoscopy
24. Patients who received any investigational drug in the past 30 days or 5 half-lives, whichever is longer
25. Pregnancy or lactation or wish to become pregnant in the coming 26 weeks

Where it's running

• Amsterdam UMC AMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Dr. K. Gecse, MD
• Email: k.b.gecse@amsterdamumc.nl
• Phone: +31-20-566-4401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single-dose MT-201 with Infliximab in healthy adults

  This early phase study tests a single dose of MT-201 given with infliximab in healthy adults to see if it is safe and how the body handles it.

  Recruiting Phase 1 Mirador Therapeutics, Inc. · San Diego, California · NCT07776782

• Infliximab plus prednisone vs prednisone alone for ICI-associated AKI

  This study tests whether adding infliximab to prednisone helps adults with kidney injury caused by cancer immunotherapy recover kidney function faster than standard prednisone alone.

  Recruiting at 2 sites Phase 4 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07683975

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Multimodal Eye Data Bank to Explore Inflammation-Related Eye Diseases

  This observational effort collects rich eye-imaging data from people with inflammatory and retinal conditions to see how the front and back of the eye relate and to build a standardized database that could support future AI tools.

  Recruiting Capital Medical University · Beijing · NCT07628946

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Infliximab level monitoring in children with inflammatory bowel disease

  This project will test whether measuring infliximab levels in saliva and leftover blood during the first infusions helps monitor and personalize treatment for children and teens (ages 3–18) with Crohn's disease or ulcerative colitis.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Italy · NCT07470502

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.